Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03771963 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT03771963 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 200 participants.
The verdict
NCT03771963, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immune response of a naturally aged lot of tetravalent dengue vaccine (TDV) in healthy participants, aged 18 to 60 years, in non-endemic country(ies) for dengue.
Interventions
- BIOLOGICAL Tetravalent Dengue Vaccine (TDV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-03-28 |
| Est. Completion | 2020-03-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03771963
The ClinicalTrials.gov registry entry for NCT03771963 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tetravalent Dengue Vaccine (TDV) is the first listed.
NCT03771963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03771963 about?
NCT03771963 is a clinical study titled "Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults". The purpose of this study is to evaluate the safety and immune response of a naturally aged lot of tetravalent dengue vaccine (TDV) in healthy participants, aged 18 to 60 years, in non-endemic country(ies) for dengue.
What is the current status of trial NCT03771963?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2019-03-28. Estimated completion is 2020-03-13.
What interventions are being tested in trial NCT03771963?
The interventions under investigation include: Tetravalent Dengue Vaccine (TDV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03771963?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.